Results 101 to 110 of about 146,743 (148)

NSD2 degradation remediates the oncogenic cistrome in t(4;14) multiple myeloma.

Blood
Hu B, Edwards JT, Modi H, Gamez J, Echeagaray O, Hess K, Ren Y, Anderson D, Larrayoz M, Zhu J, Johnson S, Deb G, Jankeel D, Janardhanan P, Leisten J, Peng S, Christoforou A, Stong N, Fontanillo C, Bjorklund CC, Hagner PR, Gandhi AK, Martinez-Climent JA, Narla RK, Lopez-Girona A, Rolfe M, Bence N, Mortensen DS, Groocock L.   +28 more
europepmc   +1 more source

Rethinking immunotherapy sequencing in multiple myeloma: a conceptual adaptive immunotherapy sequencing model. [PDF]

Front Immunol
Khalili A.
europepmc   +1 more source

Bispecific antibodies are becoming the preferred standard of care in relapsed/refractory multiple myeloma. [PDF]

Blood Adv
Janakiram M.
europepmc   +1 more source

Laboratory Identification of Pseudohypercalcemia Induced by Hyperglobulinemia in Multiple Myeloma: A Case Report. [PDF]

J Clin Lab Anal
Zhao A, Zhong F, Liu Y, Li G.
europepmc   +1 more source

Targeting the immunological synapse in multiple myeloma. [PDF]

Discov Oncol
Sumei L, Bahmani F.
europepmc   +1 more source

In Silico Analysis of Enantioselective Binding of Pomalidomide Targets for Multiple Myeloma. [PDF]

Chirality
Vardhan G, Kumar V, Kumar A, Handu S, Dhamija P.   +4 more
europepmc   +1 more source

Practical recommendations for the implementation of shared decision-making in multiple myeloma care. [PDF]

PLoS One
Broekmans J, Schoefs E, Verbeke C, De Proost L, Ten Seldam S, Duncan E, Aviv A, Shoham V, Delforge M, Vanhellemont A, Huys I.   +10 more
europepmc   +1 more source